Core Viewpoint - The article discusses a novel micro-invasive treatment platform using self-amplifying RNA (saRNA) for myocardial infarction, which shows potential for long-lasting cardiac protection through a single intramuscular injection of saNppa-LNP [4][10]. Group 1: Research Development - A research team from Columbia University developed a lipid nanoparticle delivery system for self-amplifying RNA therapy (saNppa-LNP) that requires only a single muscle injection to continuously express cardiac protective factors [4]. - The study published in the journal Science demonstrates that saNppa-LNP significantly improves cardiac function and ventricular remodeling after myocardial infarction [4][10]. Group 2: Mechanism of Action - The therapy utilizes the Nppa gene, which encodes Atrial Natriuretic Peptide (ANP), a hormone with protective cardiac functions, to enhance cardiac regeneration [6]. - The saRNA can self-replicate within cells, allowing for prolonged protein expression at low doses, which is a significant advantage over traditional mRNA therapies [6][7]. Group 3: Experimental Results - In mouse models, a single injection of saNppa-LNP led to a strong secretion of Pro-ANP, lasting at least four weeks, and resulted in improved left ventricular ejection fraction, reduced infarct size, and decreased fibrosis [7][10]. - The benefits of saNppa-LNP therapy were consistently validated in various models, including aged, atherosclerotic, and diabetic myocardial infarction models [7]. Group 4: Safety and Efficacy - Single-cell RNA sequencing analysis indicated that saNppa-LNP treatment reshaped the paracrine profile of specific endothelial and epicardial cells, creating a favorable microenvironment for regeneration [8]. - Longitudinal safety assessments revealed only transient local inflammation without signs of adaptive immune activation or systemic toxicity [8].